← Back to Search

PARP Inhibitor

Niraparib Tosylate Monohydrate for Leiomyosarcoma

Phase 2
Waitlist Available
Led By James L Chen, MD
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years after study treatment
Awards & highlights

Summary

This trial is testing whether niraparib, which blocks the PARP enzyme, can shrink tumors in patients with leiomyosarcoma.

Eligible Conditions
  • Leiomyosarcoma
  • Retroperitoneal Sarcoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years after study treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years after study treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Confirmed objective response rate (ORR)
Secondary outcome measures
Confirmed clinical benefit rate (CBR)
Incidence of adverse events (AEs)
Overall survival (OS)
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (Niraparib)Experimental Treatment1 Intervention
Patients receive niraparib PO QD. Cycles repeat every 28 days for 15 months in the absence of disease progression or unacceptable toxicity.

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor
325 Previous Clinical Trials
290,604 Total Patients Enrolled
David Liebner, MDLead Sponsor
James L Chen, MDPrincipal InvestigatorOhio State University Comprehensive Cancer Center

Media Library

Niraparib (PARP Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05174455 — Phase 2
Leiomyosarcoma Research Study Groups: Treatment (Niraparib)
Leiomyosarcoma Clinical Trial 2023: Niraparib Highlights & Side Effects. Trial Name: NCT05174455 — Phase 2
Niraparib (PARP Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05174455 — Phase 2
~0 spots leftby Dec 2024